JP2023512821A5 - - Google Patents
Info
- Publication number
- JP2023512821A5 JP2023512821A5 JP2022548039A JP2022548039A JP2023512821A5 JP 2023512821 A5 JP2023512821 A5 JP 2023512821A5 JP 2022548039 A JP2022548039 A JP 2022548039A JP 2022548039 A JP2022548039 A JP 2022548039A JP 2023512821 A5 JP2023512821 A5 JP 2023512821A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- hydrogen
- alkylene
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025279101A JP2026053548A (ja) | 2020-02-04 | 2025-12-23 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての3-ピロリジンインドール誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969894P | 2020-02-04 | 2020-02-04 | |
| US62/969,894 | 2020-02-04 | ||
| PCT/CA2021/050122 WO2021155467A1 (en) | 2020-02-04 | 2021-02-04 | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279101A Division JP2026053548A (ja) | 2020-02-04 | 2025-12-23 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての3-ピロリジンインドール誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023512821A JP2023512821A (ja) | 2023-03-29 |
| JP2023512821A5 true JP2023512821A5 (cg-RX-API-DMAC7.html) | 2024-02-13 |
| JP7824222B2 JP7824222B2 (ja) | 2026-03-04 |
Family
ID=77199114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548039A Active JP7824222B2 (ja) | 2020-02-04 | 2021-02-04 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての3-ピロリジンインドール誘導体 |
| JP2025279101A Pending JP2026053548A (ja) | 2020-02-04 | 2025-12-23 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての3-ピロリジンインドール誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025279101A Pending JP2026053548A (ja) | 2020-02-04 | 2025-12-23 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての3-ピロリジンインドール誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11453689B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4100403A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7824222B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220137085A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115380028A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021215709A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022015379A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3166940A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL295374A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009528A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021155467A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021215709A1 (en) * | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| MX2023010317A (es) * | 2021-03-02 | 2023-11-09 | Mindset Pharma Inc | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. |
| WO2022246572A1 (en) * | 2021-05-26 | 2022-12-01 | Mindset Pharma Inc. | Hallucinogen-fatty acid combination |
| KR20240017363A (ko) * | 2021-06-02 | 2024-02-07 | 세인트 조셉스 유니버시티 | 플루오린화 트립타민 화합물, 이의 유사체 및 이를 사용하는 방법 |
| CA3229361A1 (en) * | 2021-08-20 | 2023-02-23 | Abdelmalik Slassi | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto |
| EP4452939A4 (en) * | 2021-12-24 | 2025-12-10 | Kuleon Llc | SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS |
| CA3243296A1 (en) * | 2022-02-01 | 2023-08-10 | Caamtech, Inc. | PSYCHEDELIC COMPOUNDS AND THEIR THERAPEUTIC USES |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| JP2025513461A (ja) * | 2022-04-19 | 2025-04-24 | マインドセット ファーマ インコーポレイテッド | セロトニン作動薬としてのインドリン誘導体に関連する障害の治療に有用なセロトニン作動薬としてのインドリン誘導体 |
| CN117586171A (zh) * | 2022-08-12 | 2024-02-23 | 长春金赛药业有限责任公司 | 吲哚类衍生物、药物组合物及其在中枢神经领域的应用 |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| WO2025104491A1 (en) | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| TW202619712A (zh) * | 2024-09-09 | 2026-05-16 | 大陸商翼思生物醫藥(蘇州)有限公司 | 5-ht2a受體激動劑及m4活化劑之組合及其用途 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5607951A (en) | 1990-10-15 | 1997-03-04 | Pfizer Inc | Indole derivatives |
| US5559129A (en) | 1990-10-15 | 1996-09-24 | Pfizer Inc | Indole derivatives |
| US5545644A (en) | 1990-10-15 | 1996-08-13 | Pfizer Inc. | Indole derivatives |
| US5120749A (en) | 1991-02-20 | 1992-06-09 | Abbott Laboratories | Platelet activating antagonists |
| TW288010B (cg-RX-API-DMAC7.html) * | 1992-03-05 | 1996-10-11 | Pfizer | |
| AU670579B2 (en) * | 1992-04-07 | 1996-07-25 | Pfizer Inc. | Indole derivatives as 5-HT1 agonists |
| KR960701865A (ko) * | 1993-04-22 | 1996-03-28 | 데이비드 존. 우드 | 편두통에 사용하는 5-HT1 유사 효능제인 인돌 유도체(Indole Derivatives as 5-HT, -Like Agonists for Use in Migraine) |
| AP486A (en) * | 1993-04-27 | 1996-04-16 | Pfizer | Indole derivatives. |
| FR2735774B1 (fr) | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| JP2001503414A (ja) | 1996-10-31 | 2001-03-13 | ハーバー ブランチ オーシャノグラフィック インスティテューション インク. | 抗神経性炎症化合物および組成物ならびにその使用法 |
| US6100291A (en) | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| GB9816263D0 (en) | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
| US6218423B1 (en) | 1998-08-14 | 2001-04-17 | Gpi Nil Holdings, Inc. | Pyrrolidine derivatives for vision and memory disorders |
| GB9923314D0 (en) | 1999-10-01 | 1999-12-08 | Pfizer Ltd | Acylation process |
| US6841685B2 (en) | 2000-06-07 | 2005-01-11 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Methods for making bis-heterocyclic alkaloids |
| US7135479B2 (en) | 2002-09-12 | 2006-11-14 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans |
| WO2004106298A1 (en) | 2003-05-30 | 2004-12-09 | Janssen Pharmaceutica N.V. | Indole derivatives with an improved antipsychotic activity |
| WO2005062985A2 (en) * | 2003-12-23 | 2005-07-14 | American Bioscience, Inc. | Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications |
| MX2007003375A (es) | 2004-09-22 | 2007-05-07 | Janssen Pharmaceutica Nv | Inhibidores de la interaccion entre mdm2 y p53. |
| ATE489138T1 (de) | 2005-04-13 | 2010-12-15 | Neuraxon Inc | Substituierte indolverbindungen mit nos-hemmender aktivität |
| US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
| DK1981875T3 (da) | 2006-01-19 | 2014-07-14 | Janssen Pharmaceutica Nv | Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase |
| EP2029136A4 (en) * | 2006-05-22 | 2010-01-06 | Vanda Pharmaceuticals Inc | TREATMENT FOR DEPRESSION DISEASES |
| US7964728B2 (en) | 2006-07-06 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| WO2008036967A2 (en) | 2006-09-22 | 2008-03-27 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds as lasy activators |
| US20090014868A1 (en) | 2007-07-10 | 2009-01-15 | International Business Machines Corporation | Manufacturing ic chip in portions for later combining, and related structure |
| EA201000808A1 (ru) | 2007-11-16 | 2011-04-29 | Ньюраксон, Инк. | Индольные соединения и способы лечения висцеральной боли |
| US20100022581A1 (en) | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| WO2010132072A1 (en) | 2009-05-15 | 2010-11-18 | Neuraxon, Inc | Treatment or prevention of migraine by dosing at aura |
| EP2668177B1 (en) | 2011-01-28 | 2014-10-22 | Boehringer Ingelheim International GmbH | Substituted pyridinyl-pyrimidines and their use as medicaments |
| HUE039750T2 (hu) * | 2014-06-26 | 2019-02-28 | Contera Pharma Aps | Hidroxi-buspiron mozgászavarok kezelésére |
| GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
| WO2017042643A1 (en) * | 2015-09-10 | 2017-03-16 | Suven Life Sciences Limited | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators |
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| WO2018094106A2 (en) | 2016-11-16 | 2018-05-24 | University Of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES |
| CA3077053A1 (en) * | 2017-09-27 | 2019-04-04 | Ohio State Innovation Foundation | Methods and compositions for inhibition of stat3 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12090145B2 (en) | 2018-08-20 | 2024-09-17 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
| MX2021009037A (es) | 2019-01-30 | 2021-10-13 | Diamond Therapeutics Inc | Composiciones y metodos para el manejo de trastornos. |
| US12616706B2 (en) | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| US20230021957A1 (en) | 2019-12-04 | 2023-01-26 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| AU2021215709A1 (en) * | 2020-02-04 | 2022-09-01 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders |
| US20210236523A1 (en) | 2020-02-05 | 2021-08-05 | Yale University | Psychedelic treatment for headache disorders |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| WO2021116503A2 (en) | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| DK4172145T3 (da) | 2020-06-30 | 2026-07-20 | Reunion Neuroscience Inc | Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression |
| WO2022018709A1 (en) | 2020-07-21 | 2022-01-27 | Ai Pharmaceuticals Jamaica Limited | Compositions and methods for treatment of psychoses and psychotic disorders |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
-
2021
- 2021-02-04 AU AU2021215709A patent/AU2021215709A1/en active Pending
- 2021-02-04 CN CN202180026721.8A patent/CN115380028A/zh active Pending
- 2021-02-04 BR BR112022015379A patent/BR112022015379A2/pt unknown
- 2021-02-04 EP EP21751045.2A patent/EP4100403A4/en active Pending
- 2021-02-04 KR KR1020227030622A patent/KR20220137085A/ko not_active Ceased
- 2021-02-04 IL IL295374A patent/IL295374A/en unknown
- 2021-02-04 CA CA3166940A patent/CA3166940A1/en active Pending
- 2021-02-04 WO PCT/CA2021/050122 patent/WO2021155467A1/en not_active Ceased
- 2021-02-04 MX MX2022009528A patent/MX2022009528A/es unknown
- 2021-02-04 JP JP2022548039A patent/JP7824222B2/ja active Active
- 2021-07-28 US US17/387,864 patent/US11453689B2/en active Active
-
2022
- 2022-08-02 US US17/879,320 patent/US12054504B2/en active Active
-
2024
- 2024-06-19 US US18/747,540 patent/US20240336641A1/en active Pending
-
2025
- 2025-12-23 JP JP2025279101A patent/JP2026053548A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513679A5 (cg-RX-API-DMAC7.html) | ||
| JP2023553094A5 (cg-RX-API-DMAC7.html) | ||
| IL295371A (en) | Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders | |
| JP2024508922A5 (cg-RX-API-DMAC7.html) | ||
| JP2023513680A5 (cg-RX-API-DMAC7.html) | ||
| JP5586577B2 (ja) | 架橋複素環化合物およびその使用 | |
| JP2024508545A5 (cg-RX-API-DMAC7.html) | ||
| JP6933964B2 (ja) | ヘテロアリール化合物およびそれらの使用方法 | |
| JP2025501629A5 (cg-RX-API-DMAC7.html) | ||
| JP2017502073A (ja) | 置換ベンゾオキサジン及び関連化合物 | |
| AR059016A4 (es) | Derivados de aril-isoxazol-4-il-imidazo[1,2-a]piridina, metodo de preparacion, medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos. | |
| CY1114702T1 (el) | Νεοι εναnτιομερως καθαροι βητα αγωνιστες, μεθοδος για την παραγωγη τους και χρηση αυτων ως φαρμακων | |
| JP2015514073A (ja) | スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンbace阻害剤、ならびにその組成物および使用 | |
| AU2021262281B2 (en) | 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof | |
| JP2006521345A (ja) | ニコチン性アセチルコリン受容体の正のアロステリック調節剤 | |
| JP2015523406A5 (cg-RX-API-DMAC7.html) | ||
| CA3201080A1 (en) | 3-cyclic amine-indole derivatives as serotonergic agents for the treatment of cns disorders | |
| JP2025508323A5 (cg-RX-API-DMAC7.html) | ||
| JP2024542881A (ja) | Kv7.2阻害剤としての新規ヘテロアリール-尿素化合物 | |
| JP2025502712A (ja) | シクロプロピル化合物 | |
| JP2021506806A (ja) | 置換アゼチジンジヒドロチエノピリジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用 | |
| JP2025513462A5 (cg-RX-API-DMAC7.html) | ||
| JP2019521964A5 (cg-RX-API-DMAC7.html) | ||
| JP2024540583A (ja) | Kv7.2エンハンサーとしてのピリジン化合物 | |
| CA3229358A1 (en) | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |